Hospitalized adult (18–80 years) patients with COVID-19 (symptoms for 3–14 days) requiring supplemental oxygen. NOT receiving other JAK inhibitors or anti-IL-6 therapy. Enrollment period: NA. Here, IL6 is linked to COVID-19.